TY - JOUR
T1 - Hybrid nanoparticles for combination therapy of cancer
AU - He, Chunbai
AU - Lu, Jianqin
AU - Lin, Wenbin
N1 - Funding Information:
We thank NIH ( U01-CA151455 ) and the University of Chicago Medicine Comprehensive Cancer Center (NIH CCSG: P30 CA014599 ) for funding support.
Publisher Copyright:
© 2015 Elsevier B.V. All rights reserved.
PY - 2015/12/10
Y1 - 2015/12/10
N2 - Nanoparticle anticancer drug delivery enhances therapeutic efficacies and reduces side effects by improving pharmacokinetics and biodistributions of the drug payloads in animal models. Despite promising preclinical efficacy results, monotherapy nanomedicines have failed to produce enhanced response rates over conventional chemotherapy in human clinical trials. The discrepancy between preclinical data and clinical outcomes is believed to result from the less pronounced enhanced permeability and retention (EPR) effect in and the heterogeneity of human tumors as well as the intrinsic/acquired drug resistance to monotherapy over the treatment course. To address these issues, recent efforts have been devoted to developing nanocarriers that can efficiently deliver multiple therapeutics with controlled release properties and increased tumor deposition. In ideal scenarios, the drug or therapeutic modality combinations have different mechanisms of action to afford synergistic effects. In this review, we summarize recent progress in designing hybrid nanoparticles for the co-delivery of combination therapies, including multiple chemotherapeutics, chemotherapeutics and biologics, chemotherapeutics and photodynamic therapy, and chemotherapeutics and radiotherapy. The in vitro and in vivo anticancer effects are also discussed.
AB - Nanoparticle anticancer drug delivery enhances therapeutic efficacies and reduces side effects by improving pharmacokinetics and biodistributions of the drug payloads in animal models. Despite promising preclinical efficacy results, monotherapy nanomedicines have failed to produce enhanced response rates over conventional chemotherapy in human clinical trials. The discrepancy between preclinical data and clinical outcomes is believed to result from the less pronounced enhanced permeability and retention (EPR) effect in and the heterogeneity of human tumors as well as the intrinsic/acquired drug resistance to monotherapy over the treatment course. To address these issues, recent efforts have been devoted to developing nanocarriers that can efficiently deliver multiple therapeutics with controlled release properties and increased tumor deposition. In ideal scenarios, the drug or therapeutic modality combinations have different mechanisms of action to afford synergistic effects. In this review, we summarize recent progress in designing hybrid nanoparticles for the co-delivery of combination therapies, including multiple chemotherapeutics, chemotherapeutics and biologics, chemotherapeutics and photodynamic therapy, and chemotherapeutics and radiotherapy. The in vitro and in vivo anticancer effects are also discussed.
KW - Co-delivery
KW - Combination therapy of cancer
KW - Hybrid nanoparticle
KW - Synergistic effect
UR - http://www.scopus.com/inward/record.url?scp=84947254613&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84947254613&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2015.09.029
DO - 10.1016/j.jconrel.2015.09.029
M3 - Article
C2 - 26387745
AN - SCOPUS:84947254613
SN - 0168-3659
VL - 219
SP - 224
EP - 236
JO - Journal of Controlled Release
JF - Journal of Controlled Release
ER -